Management of <i>BRAF</i> Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives.

Front Oncol · 2021 · PMC8027060 · PMID 33842313

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

difference was apparentno p-value reported

A pooled analysis of four phase III studies in mCRC reported significantly worse PFS and OS outcomes for BRAF -mutant mCRC in comparison with BRAF wild-type mCRC with microsatellite-stable tumors, but no significant difference was apparent between BRAF- mutant and BRAF wild-type mCRC with MSI-high tumors ( 13 ).

also in 830 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.